Cargando…

Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy

OBJECTIVE: Diabetes mellitus is a chronic disease related to a significant impact in both epidemiologic and economic terms. In Italy, around 3.6 million people are affected by diabetes and this number is expected to increase significantly in the next few years. As recommended by current national and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzoni, Valentina, Baccetti, Fabio, Genovese, Stefano, Torre, Enrico, Turchetti, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700761/ https://www.ncbi.nlm.nih.gov/pubmed/29200879 http://dx.doi.org/10.2147/CEOR.S141477

Ejemplares similares

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
por: Shin, Yujin, et al.
Publicado: (2020)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective
por: Lorenzoni, Valentina, et al.
Publicado: (2021)

Add-On Complementary Medicine in Cancer Care: Evidence in Literature and Experiences of Integration
por: Rossi, Elio, et al.
Publicado: (2017)

Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study
por: Sato, Ai, et al.
Publicado: (2019)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Antidiabetic Effects of Add-On Gynostemma pentaphyllum Extract Therapy with Sulfonylureas in Type 2 Diabetic Patients
por: Huyen, V. T. T., et al.
Publicado: (2012)

How Italy Tweeted about COVID-19: Detecting Reactions to the Pandemic from Social Media
por: Lorenzoni, Valentina, et al.
Publicado: (2022)

Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study
por: Mamza, Jil, et al.
Publicado: (2015)

Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
por: Sharma, Manuj, et al.
Publicado: (2017)

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis
por: Brath, Helmut, et al.
Publicado: (2017)

Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
por: Jeon, Won Kyeong, et al.
Publicado: (2021)

Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: A comparative study
por: Mahajan, Rajiv, et al.
Publicado: (2010)

SAT-139 Clinical Impact of Oral Semaglutide Compared with Sitagliptin in T2D on Metformin ± Sulfonylurea: The Pioneer 3 Trial
por: Rosenstock, Julio, et al.
Publicado: (2019)

Correction to: “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Jeon, Won Kyeong, et al.
Publicado: (2022)

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
por: Lorenzoni, Valentina, et al.
Publicado: (2018)

Scoping review and bibliometric analysis of Big Data applications for Medication adherence: an explorative methodological study to enhance consistency in literature
por: Pirri, Salvatore, et al.
Publicado: (2020)

The social cost of chronic kidney disease in Italy
por: Turchetti, Giuseppe, et al.
Publicado: (2016)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
por: Ghetti, Gianni, et al.
Publicado: (2023)

Telerehabilitation after total knee replacement in Italy: cost-effectiveness and cost-utility analysis of a mixed telerehabilitation-standard rehabilitation programme compared with usual care
por: Fusco, Francesco, et al.
Publicado: (2016)

Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
por: Kutoh, Eiji
Publicado: (2011)

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials
por: Ommen, Elizabeth S., et al.
Publicado: (2015)

Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study
por: Hougen, Ingrid, et al.
Publicado: (2021)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
por: Mezquita Raya, Pedro, et al.
Publicado: (2013)

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes
por: Giampietro, Ottavio, et al.
Publicado: (2013)

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)
por: Kesavadev, Jothydev, et al.
Publicado: (2017)

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis
por: HOU, LIQIONG, et al.
Publicado: (2015)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Response to Letter Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis”
por: Park, Kyung Woo
Publicado: (2022)

Cost-effectiveness of treatment optimisation with biomarkers for immunotherapy in solid tumours: a systematic review protocol
por: Mucherino, Sara, et al.
Publicado: (2021)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

Cost-effectiveness analysis of stand-alone or combined non-invasive imaging tests for the diagnosis of stable coronary artery disease: results from the EVINCI study
por: Lorenzoni, Valentina, et al.
Publicado: (2019)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Wan, Heng, et al.
Publicado: (2016)

A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes
por: Takai, Masahiko, et al.
Publicado: (2020)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c6amgpgv26m52epcm0oreadlla